公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2018 | Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan | CHEN-HUA LIU ; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 41 | 41 | |
2005 | Comparison of a 6-month course peginterferon α-2b plus ribavirin and interferon α-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan | Lee S.-D.; Yu M.-L.; Cheng P.-N.; Lai M.-Y.; Chao Y.-C.; Hwang S.-J.; Chang W.-Y.; Chang T.-T.; Hsieh T.-Y.; CHUN-JEN LIU ; DING-SHINN CHEN | Journal of Viral Hepatitis | 78 | 70 | |
2014 | Complete activation of autophagic process attenuates liver injury and improves survival in septic mice | Lin C.-W.; Lo S.; Perng D.-S.; Wu D.B.-C.; PO-HUANG LEE ; Chang Y.-F.; Kuo P.-L.; Yu M.-L.; Yuan S.-S.F.; Hsieh Y.-C. | Shock | 62 | 60 | |
2013 | Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: A multicentre study | Dai C.-Y.; TAI-CHUNG TSENG ; Wong G.L.H.; Huang J-F.; Wong V.W.S.; CHUN-JEN LIU ; Yu M.-L.; Chuang W.-L.; JIA-HORNG KAO ; Yuen Chan H.L.; DING-SHINN CHEN | Journal of Antimicrobial Chemotherapy | 20 | 19 | |
1994 | Correlation of liquid-liquid phase equilibria using the SAFT equation of state | Yu M.-L.; Chen Y.-P. | Fluid Phase Equilibria | 34 | 28 | |
2017 | Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1 | JIA-HORNG KAO ; Yu M.-L.; Peng C.-Y.; Heo J.; Chu C.-J.; Chang T.-T.; Lee Y.-J.; Hu T.-H.; Yoon K.T.; Paik S.W.; Lim Y.S.; Ahn S.H.; Isakov V.; McPhee F.; Hu W.; Scott Swenson E.; Yin P.D.; Treitel M. | Journal of Gastroenterology and Hepatology (Australia) | 17 | 12 | |
2019 | Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium | Huang C.-F.; Iio E.; Jun D.W.; Ogawa E.; Toyoda H.; Hsu Y.-C.; Haga H.; Iwane S.; Enomoto M.; Lee D.H.; Wong G.; CHEN-HUA LIU ; Tada T.; Chuang W.-L.; Cheung R.; Hayashi J.; Tseng C.-H.; Yasuda S.; Tran S.; Kam L.; Henry L.; Jeong J.Y.; Nomura H.; Park S.H.; Nakamuta M.; Huang J.-F.; Tai C.-M.; Lo G.-H.; Lee M.-H.; Yang H.-I.; JIA-HORNG KAO ; Tamori A.; Eguchi Y.; Ueno Y.; Furusyo N.; Tanaka Y.; Yu M.-L.; Nguyen M.H.; For the REAL-C Investigators | Hepatology International | 31 | 27 | |
1994 | Early development of Yu-Cheng children born seven to twelve years after the Taiwan PCB outbreak | Yue Leon Guo ; Chen Y.-C.; Yu M.-L.; Hsu C.-C. | Chemosphere | 28 | 30 | |
2011 | Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy | TAI-CHUNG TSENG ; Yu M.-L.; CHUN-JEN LIU ; Lin C.-L.; Huang Y.-W.; Hsu C.-S.; CHEN-HUA LIU ; Kuo S.F.-T.; Pan C.J.-H.; Yang S.-S.; Su C.-W.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Antiviral Therapy | 76 | 70 | |
2019 | Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions | Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; SHIH-JER HSU ; CHEN-HUA LIU ; Huang C.-F.; Su C.-W.; Huang J.-F.; CHUN-JEN LIU ; JIA-HORNG KAO ; Chuang W.-L.; PEI-JER CHEN ; DING-SHINN CHEN | Journal of the Formosan Medical Association | 10 | 8 | |
2021 | Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan | Cheng P.-N.; Chen C.-Y.; Yu M.-L.; Lin C.-C.; Lin C.-Y.; Peng C.-Y.; Tseng K.-C.; Lo C.-C.; Tseng I.-H.; CHUN-JEN LIU | Journal of Microbiology, Immunology and Infection | 5 | 4 | |
2005 | The endocrine and reproductive function of the female Yucheng adolescents prenatally exposed to PCBs/PCDFs | Yang C.-Y.; Yu M.-L.; Guo H.-R.; Lai T.-J.; Hsu C.-C.; Lambert G.; Yue Leon Guo | Chemosphere | 56 | 50 | |
2020 | Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH) | Huang C.-F.; Lai H.-C.; Chen C.-Y.; Tseng K.-C.; Kuo H.-T.; Hung C.-H.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Yu M.-L. | The American journal of gastroenterology | 20 | 17 | |
2022 | Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals | Chen Y.-C.; Chang T.-S.; Chen C.-H.; Cheng P.-N.; Lo C.-C.; Mo L.-R.; Chen C.-T.; Huang C.-F.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; Dai C.-Y.; JIA-HORNG KAO ; Chuang W.-L.; Lin H.-C.; Chen C.-Y.; Tseng K.-C.; Yu M.-L.; on behalf of TACR investigators | Viruses | 1 | 1 | |
2021 | Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan | Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; CHUN-JEN LIU ; Dai C.-Y.; JIA-HORNG KAO ; Chuang W.-L.; Lin H.-C.; Yu M.-L. | Liver International | 25 | 23 | |
2006 | Genetic predisposition of responsiveness to therapy for chronic hepatitis C | Hwang Y.; Chen E.Y.; Gu Z.J.; Chuang W.-L.; Yu M.-L.; Lai M.-Y.; Chao Y.-C.; Lee C.-M.; Wang J.-H.; Dai C.-Y.; Bey M.S.-J.; Liao Y.-T.; PEI-JER CHEN ; Chen D.-S. | Pharmacogenomics | 26 | 23 | |
2010 | HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses | Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; CHI-LING CHEN ; JIA-HORNG KAO ; Lai M.-Y.; CHEN-HUA LIU ; TUNG-HUNG SU ; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; PEI-JER CHEN ; CHUN-JEN LIU ; DING-SHINN CHEN | Journal of Infectious Diseases | 42 | 37 | |
2013 | Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis | Lin C.-W.; Lin C.-C.; Mo L.-R.; Chang C.-Y.; Perng D.-S.; Hsu C.-C.; Lo G.-H.; Chen Y.-S.; Yen Y.-C.; Hu J.-T.; Yu M.-L.; PO-HUANG LEE ; Lin J.-T.; Yang S.-S. | Journal of Hepatology | 111 | 106 | |
2020 | Hepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: A practice implication | Ogawa E.; Toyoda H.; Iio E.; Jun D.W.; Huang C.-F.; Enomoto M.; Hsu Y.-C.; Haga H.; Iwane S.; Wong G.; Lee D.H.; Tada T.; CHEN-HUA LIU ; Chuang W.-L.; Hayashi J.; Cheung R.; Yasuda S.; Tseng C.-H.; Takahashi H.; Tran S.; Yeo Y.H.; Henry L.; Barnett S.D.; Nomura H.; Nakamuta M.; Dai C.-Y.; Huang J.-F.; Yang H.-I.; Lee M.-H.; Jun M.J.; JIA-HORNG KAO ; Eguchi Y.; Ueno Y.; Tamori A.; Furusyo N.; Yu M.-L.; Tanaka Y.; Nguyen M.H.; Ahn S.B.; Azuma K.; Dohmen K.; Jeong J.Y.; Jung J.H.; Kajiwara E.; Kato M.; Kawano A.; Koyanagi T.; Ooho A.; Park S.H.; Satoh T.; Shimoda S.; Song D.S.; Takahashi K.; Yeh M.-L.; Yoon E.L.; Real-World Evidence from the Asia Liver Consortium Investigators | Clinical Infectious Diseases | 26 | 19 | |
2021 | Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort) | Hsu W.-F.; Tsai P.-C.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. | Journal of Gastroenterology and Hepatology (Australia) | 7 | 10 |